Goldman Sachs initiated coverage of JBS (JBS) with a Buy rating and $19.50 price target JBS offers one of the best risk/rewards across global protein stocks, the analyst tells investors in a research note. The firm likes the company’s “highly diversified” portfolio, “consistent execution,” growth algorithm, and “appealing” free cash flow generation. It views the stock’s valuation as “undemanding” at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks